Trial Profile
An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Sponsors Bio Products Laboratory
- 28 Jul 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database record (Global end date: 2008-04-09).
- 21 Apr 2014 New trial record